BUZZ-Ensysce Biosciences rises on US government grant for its pain relief drug

Reuters08-27

** Shares of drug developer Ensysce Biosciences rise 63.6% to 71 cents premarket

** Co says it has received a $14 mln multi-year grant from the National Institutes of Health and National Institute on Drug Abuse for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection

** Funding from this award will be available over a period of about three years, allowing for the completion of an early-stage trial on the drug

** With this funding, adding to the two prior grants of over $26 mln, Ensysce intends to quickly drive PF614-MPAR through clinical development, co says

** The drug is designed to provide optimal pain relief at prescribed doses, yet limit accidental or intentional overdose by 'shutting down' opioid release if too much active drug is consumed - ENSC

** Up to last close, stock down 58.7% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment